A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PIPSeN
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 31 Jul 2017 Planned number of patients changed from 500 to 600.
- 21 Oct 2015 New trial record